Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the world; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital. This partnership aims to better understand the drug's mechanism and potentially accelerate its path to market.
In addition to its work in MS, Quantum BioPharma developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses a widespread issue: the temporary but significant impairment of cognitive and motor functions caused by alcohol consumption. Unlike existing hangover remedies that only treat symptoms, unbuzzd targets the underlying metabolic pathways to mitigate both intoxication and its aftereffects.
The dual focus on chronic and acute neurological conditions positions Quantum BioPharma at the intersection of two large and growing markets. The global multiple sclerosis therapeutics market was valued at over $23 billion in 2023 and is expected to expand as new disease-modifying therapies emerge. Meanwhile, the market for alcohol hangover cures and intoxication management is less defined but represents a significant consumer health opportunity. By advancing Lucid-MS through clinical trials and commercializing unbuzzd, the company is leveraging its research expertise to address distinct patient needs.
Investors and stakeholders can follow the latest updates from Quantum BioPharma via the company’s newsroom at https://ibn.fm/QNTM. The company’s progress in both programs will be closely watched, as successful development could provide new options for millions of patients who currently have limited or inadequate treatments.
